Are you sure you are not the author of this publication?
Adriana Simionescu-Bankston Christophe Pichavant James P. Canner Luciano H. Apponi Yanru Wang Craig Steeds John T. Olthoff Joseph J. Belanto James M. Ervasti Grace K. Pavlath
...
Published in
AJP Cell Physiology
Myoblast fusion is critical for proper muscle growth and regeneration. During myoblast fusion, the localization of some molecules is spatially restricted; however, the exact reason for such localization is unknown. Creatine kinase B (CKB), which replenishes local ATP pools, localizes near the ends of cultured primary mouse myotubes. To gain insight...
Are you sure you are not the author of this publication?
Christophe Pichavant Grace K Pavlath
Published in
Skeletal Muscle
Background
Myofibers with an abnormal branching cytoarchitecture are commonly found in muscular dystrophy and in regenerated or aged nondystrophic muscles. Such branched myofibers from dystrophic mice are more susceptible to damage than unbranched myofibers in vitro, suggesting that muscles containing a high percentage of these myofibers are more ...
Are you sure you are not the author of this publication?
Christophe Pichavant Jacques Tremblay
Published in
Methods in Molecular Biology
Gene therapy is a promising approach for the treatment of a variety of disorders including genetic diseases and cancer. Among the viral vectors used in gene therapy, the lentiviral vector, based on HIV-1, is the only integrative vector able to transduce nondividing cells. The first generation of lentiviral vector was established in 1996. Since then...
Are you sure you are not the author of this publication?
Christophe Pichavant Annemieke Aartsma-Rus Paula R Clemens Kay E Davies George Dickson Shin'ichi Takeda Steve D Wilton Jon A Wolff Christine I Wooddell Xiao Xiao
...
Published in
Molecular Therapy
Duchenne muscular dystrophy (DMD) is a genetic disease affecting about one in every 3,500 boys. This X-linked pathology is due to the absence of dystrophin in muscle fibers. This lack of dystrophin leads to the progressive muscle degeneration that is often responsible for the death of the DMD patients during the third decade of their life. There ar...
Are you sure you are not the author of this publication?
Christophe Pichavant Pierre Chapdelaine Daniel Cerri Joao Bizario Jacques Tremblay
Published in
Human Gene Therapy
Duchenne muscular dystrophy (DMD) is an X-linked genetic disease characterized by the absence of dystrophin (427 kDa). An approach to eventually restore this protein in patients with DMD is to introduce into their muscles a plasmid encoding dystrophin cDNA. Because the phenotype of the dystrophic dog is closer to the human phenotype than is the mdx...
Are you sure you are not the author of this publication?
Christophe Pichavant Pierre Chapdelaine Daniel G Cerri Jean-Christophe Dominique Simon P Quenneville Daniel Skuk Joe N Kornegay João CS Bizario Xiao Xiao Jacques P Tremblay
...
Published in
Molecular Therapy
Duchenne muscular dystrophy (DMD) is characterized by the absence of dystrophin. Several previous studies demonstrated the feasibility of delivering microdystrophin complementary DNA (cDNA) into mouse and normal nonhuman primate muscles by ex vivo gene therapy. However, these animal models do not reproduce completely the human DMD phenotype, while ...
Are you sure you are not the author of this publication?
P Chapdelaine Christophe Pichavant J Rousseau F Pâques J P Tremblay
Published in
Gene Therapy
Mutations in Duchenne muscular dystrophy (DMD) are either inducing a nonsense codon or a frameshift. Meganucleases (MGNs) can be engineered to induce double-strand breaks (DSBs) at specific DNA sequences. These breaks are repaired by homologous recombination or by non-homologous end joining (NHEJ), which results in insertions or deletions (indels) ...
Are you sure you are not the author of this publication?
Lionel Stephan Christophe Pichavant Manaf Bouchentouf Philippe Mills Geoffrey Camirand Saloua Tagmouti David Rothstein Jacques Tremblay
Published in
Cell transpantation
A mixed-chimerism approach is a major goal to circumvent sustained immunosuppression, but most of the proposed protocols need antibody treatment or host irradiation. Another promising experience involves bu-sulfan combined with cyclophosphamide treatment. Additionally, recent publications demonstrated that, differing from busulfan, treosulfan admin...